Metastatic Colorectal Cancer
Conditions
Brief summary
Overall Survival
Detailed description
PFS as assessed by the investigator per RECIST 1.1, ORR as assessed by the investigator per RECIST 1.1, DOR as assessed by the investigator per RECIST 1.1, Incidence and severity of Es, SAEs and adverse events of special interest (AESIs), Plasma concentration of XL092 given in combination with atezolizumab, serum concentration of atezolizumab given in combination with XL092, the incidence of antidrug antibody (ADA) response against atezolizumab given in combination with XL092.
Interventions
DRUGXL092
DRUGTecentriq 1 200 mg concentrate for solution for infusion
Sponsors
Exelixis Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS as assessed by the investigator per RECIST 1.1, ORR as assessed by the investigator per RECIST 1.1, DOR as assessed by the investigator per RECIST 1.1, Incidence and severity of Es, SAEs and adverse events of special interest (AESIs), Plasma concentration of XL092 given in combination with atezolizumab, serum concentration of atezolizumab given in combination with XL092, the incidence of antidrug antibody (ADA) response against atezolizumab given in combination with XL092. | — |
Countries
Belgium, France, Germany, Hungary, Poland, Portugal, Spain
Outcome results
None listed